Immunogenicity of protein therapeutics.

  title={Immunogenicity of protein therapeutics.},
  author={Anne S De Groot and David W Scott},
  journal={Trends in immunology},
  volume={28 11},
Protein therapeutics, such as monoclonal antibodies, enzymes and toxins, hold significant promise for improving human health. However, repeated administration of protein therapeutics, whether natural or recombinant, often leads to the induction of undesirable anti-drug antibodies (ADAs), which interfere with or neutralize the effect of the drug. Although an immune response to foreign proteins can be expected and is well understood, the basis for the development of responses to therapeutic… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 135 extracted citations

Resistance to Immunotoxins in Cancer Therapy

Resistance to Targeted Anti-Cancer Therapeutics • 2015
View 7 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 66 references

Clinical validation of the ‘‘in-silico’’ prediction of immunogenicity of a human recombinant therapeutic protein

E Koren
Cell. Immunol • 2007

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

S Gupta
J. Immunol. Methods • 2007

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects

Tobery, T.W
AIDS Res. Hum. Retroviruses • 2006

Similar Papers

Loading similar papers…